Safety and tolerability of CI-979 in patients with alzheimer's disease
- 23 June 1995
- journal article
- clinical trial
- Published by Elsevier in Life Sciences
- Vol. 57 (5) , 503-510
- https://doi.org/10.1016/0024-3205(95)00283-c
Abstract
No abstract availableKeywords
This publication has 28 references indexed in Scilit:
- Pharmacokinetic simulations of spect quantitation of the M2 muscarinic neuroreceptor subtype in disease states using radioiodinated (R,R)-41QNBLife Sciences, 1992
- Coupling of ml Muscarinic Receptors to G Protein in Alzheimer DiseaseAlzheimer Disease & Associated Disorders, 1991
- Neurotransmitter changes in alzheimer's disease: Implications to diagnostics and therapyJournal of Neuroscience Research, 1990
- Cholinergic nicotinic and muscarinic receptors in dementia of Alzheimer, Parkinson and Lewy body typesJournal Of Neural Transmission-Parkinsons Disease and Dementia Section, 1990
- (±)-cis-2-Methyl-spiro(1,3-oxathiolane-5,3′) quinuclidine (AF102B): A new M1 agonist attenuates cognitive dysfunctions in AF64A-treated ratsNeuroscience Letters, 1989
- Anticholinergic Sensitivity in Patients With Dementia of the Alzheimer Type and Age-Matched ControlsArchives of General Psychiatry, 1987
- Muscarinic Binding and Choline Acetyltransferase in Postmortem Brains of Demented PatientsCanadian Journal of Neurological Sciences, 1986
- Clinical Studies of the Cholinergic Deficit in Alzheimer's DiseaseJournal of the American Geriatrics Society, 1985
- Alzheimer's Disease: A Disorder of Cortical Cholinergic InnervationScience, 1983
- Alzheimer's Disease and Senile Dementia: Loss of Neurons in the Basal ForebrainScience, 1982